Last Chance to Save $200!
Prices Increase This Friday.
|
|
|
In just three weeks Fierce JPM Week will be returning to San Francisco on January 9-10th and a who's who in Pharma and Biotech will be coming together to share their experiences, insights and thoughts on the upcoming year's hottest topics.
Brought to you by the award-winning editors behind Fierce Pharma and Fierce Biotech, our 2024 program has two full days of insights covering the Inflation Reduction Act, biopharma M&A, advancements and challenges in gene therapy, IPOs, Oncology's next frontier and more! Don't miss this all-star lineup of speakers and join over 500 senior biotech and pharma executives at this one-of-a-kind event focused on learning, networking and connecting. Below is a snapshot of new speakers and can't-miss sessions you won't find anywhere else! VIEW THE AGENDA>> Register now and save $200 with the Advanced Rate! Prices increase this Friday and only 35 passes are left at this rate. Don't wait to secure your spot now at the lowest available price. |
|
|
Johanna Mercier Chief Commercial Officer Gilead |
| Marianne De Backer
Chief Executive Officer and Director
Vir Biotechnology, Inc. |
| Robert Plenge
EVP, Chief Research Officer, Head of Research
Bristol-Myers Squibb |
|
|
Daejin Abidoye
Vice President, Therapeutic Area Head Solid Tumor
AbbieVie |
| Issei Tsukamoto
SVP and Head of GlobalBusiness Development
Astellas Pharma Inc. |
| Elizabeth Naldi Jacob
Head of Oncology BD & Headquarters Transactions
Merck |
|
|
Chris McDonald
SVP and Global Head of Technical Operations
Kite Pharma |
| Morten Sogaard
President and Division Head of Research and Technical Operations
Astellas Gene Therapies |
| Kate Haviland
Chief Executive Officer
Blueprint Medicines |
|
|
| Crossovers, Megarounds and IPOs: Biotechs Always Find a Way Exploring the Inflation Reduction Act: Pharma's Legal Battles and the Future of InnovationA Look at Biopharma M&A and Shifting Deal DynamicsAdvancements and Challenges in Cell & Gene Therapy Manufacturing Oncology's Next Frontier: ADCs, Radiopharma and the Future of Cancer TreatmentRevolutionizing Healthcare: The Impact of AI Disruption in Clinical Trials |
Exclusive Executive Interviews by the Fierce Editorial Team: |
| Johanna Mercier, Chief Commercial Officer, Gilead Shreeram Aradhye, President, Development and Chief Medical Officer, NovartisShehnaaz Suliman, Chief Executive Officer, ReCode Therapeutics Marianne De Backer, Chief Executive Officer, Vir BiotechnologyRobert Plenge, EVP, Chief Research Officer, Head of Research, Bristol-Myers Squibb Jürgen Eckhardt, EVP, Head of Leaps by Bayer and Head of Pharmaceuticals Business Development, Licensing & Open Innovation, Bayer Pharmaceuticals |
|
|
Limited Partnership Opportunities Left! |
|
|
| | | 2 Days Great Content and Opportunities to Network |
|
|
| Position your company as a thought leader, promote your brand and engage with leading Biotech and Pharma Executives. Contact us today to learn why Fierce JPM Week is the right show for you! |
|
|
Thank You to Our Partners |
|
|
If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017 Contact Us
© 2022 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
|
|
|
